Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGARO UC 302 ontamalimab induction study in moderate to severe ulcerative colitis
2017-000572-28Phase 3Completed
- Sponsor
- Takeda
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Ontamalimab with Placebo (2 arms). Primary endpoint: Remission at Week 12. Started Sep 2017; status: completed.
02
Drugs
ontamalimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2017-000572-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000572-28.